Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer
Status:
Withdrawn
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This study will assess the effectiveness of CP- 751,871 when given in combination with
docetaxel to women with the first occurrence of advanced breast cancer disease. The
effectiveness will be measured by progression-free survival duration. Patients will be
followed for 2 years from the date of randomization.